KTN's online platform helps you to make the connections you need


The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.


The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

« go back

NICE consults on plans to support new device for treating enlarged prostate glands

NICE is asking for views on its plans to support using a device for treating enlarged prostate glands – benign prostatic hyperplasia – in a consultation opening today (Tuesday 26 January).

The draft medical technology guidance provisionally recommends the use of the GreenLight XPS 180 W laser system in non-high-risk patients, which means men who don’t have an increased risk of bleeding, whose prostates are smaller than 100 ml and who don’t have urinary retention.

Prostate enlargement is a common condition in older men – around 60% of men aged 60 or over have the condition.  An enlarged prostate can push against the urethra, making it difficult for a man to pass urine. It may also lead to repeated urinary tract infections, urinary retention and sleep problems due to the urge to urinate in the night, but the condition doesn’t pose other direct risks to health.

The device, GreenLight XPS 180 W, involves using a laser to vaporise excess prostate tissue, so easing the blocked urethra and leaving a clear channel for urine to flow. The claimed benefits of the system include a quicker return to normal activity following treatment, shorter hospital stay because the procedure can be done as a day-case, and reduction in pain leading to improved quality of life.

The draft guidance notes that there’s currently not enough evidence to support the use of the device in high-risk patients so recommends data collection.  It also proposes that where GreenLight XPS 180 W is used, urology services should be redesigned to ensure that facilities for day-case surgery are available. An estimated saving of up £60 per patient could be made using this device when compared with the procedure transurethral resection of the prostate (TURP).

Professor Carole Longson MBE, Director of the NICE Centre for Health Technology Evaluation, said: “This draft guidance on GreenLight XPS 180 W provisionally supports the use of this device for men with an enlarged prostate who don’t have high risk factors including increased risk of bleeding. The evidence examined by the independent Medical Technologies Advisory Committee indicates that using the device may benefit patients by needing a shorter hospital stay and quicker return to normal activities, and is also likely to benefit the NHS by saving money. There isn’t enough high quality evidence to make provisional recommendations on GreenLight’s use in treating enlarged prostates in men classed as high risk, so we propose that specialists collaborate to collect and publish data for these patients to improve the evidence base. We welcome comments on the draft guidance as part of this consultation.”

More information on the medical technology draft guidance consultation for GreenLight XPS 180 W  is available at http://www.nice.org.uk. The consultation closes on 23 Feb 2016